Introduction
Hepatitis E Virus (HEV), is a small, non-enveloped spherical particle of about 32-34nm in diameter and has a single stranded, positive sense RNA genome of approximately 7.5kb that is surrounded by an icosahedral capsid 1 . It is the only member of the genus Hepevirus and has four genotypes capable of causing human infection. 2, 3 Hepatitis E virus (HEV) infection is a major public health concern especially in sub-Saharan Africa among other developing countries. 4, 5 It is one of the most common causes of acute hepatitis and jaundice in the world and has affected about one-third of the world's population. 6 Annually, about 20 million new cases and 33 million acute cases of HEV infection occur globally and HEV-related hepatic failure is responsible for approximately 56,600 deaths per year. 7, 8 While it is established that HEV transmission occurs predominantly via the fecal-oral route 9,10 , parenteral, person-to-person, perinatal mode of transmission and eating undercooked wild boar, deer and pork have also been suggested. [11] [12] [13] [14] In developing countries, infection occurs both sporadically and as an epidemic, affecting a large proportion of the population. 15 In human population, prevalence of anti-HEV varies from one population to another, with significant increase noted among pregnant women and children <2yearrs old. 4 HEV infection is usually asymptomatic and self-limiting 16 , however, in some cases, acute infection may develop to fulminant hepatitis with high mortality especially among pregnant women in their third trimester 17 ,even as chronic forms of HEV have been documented among different populations. [18] [19] [20] Diagnosis of HEV infection is based on detection of anti-HEV IgM, anti-HEV lgG and HEV RNA. Specifically, the presence of anti-HEV IgM is a marker of acute HEV infection. 21 Despite, the significance of HEV in public health, especially in resource limited regions of the world, data reporting remained suboptimal, consequent of inadequate surveillance system. 22 In Nigeria, there exists dearth of information on prevalence and circulation of HEV infectionin the population. In a bid to bridge this knowledge gap, we attempted, in this study, to describe acute HEV infection among selected population groups in two geographical regions in Nigeria.
Methodology
Seven hundred and fifty (750) plasma samples were randomly selected from a pool of 1,115 samples previously collected for viral hepatitis studies. The 1,115 plasma samples were collected from consenting apparently healthy community dwellers and ante-natal clinic attendees who participated in our previous studies conducted between September 2012 and August 2013. 
Discussion
In this study, we report HEV IgM rate of 0.4% in the pregnant women cohort, and zero prevalence rate among asymptomatic community dwellers in two different geographical regions of Nigeria. Our finding is in congruence with the rates of 0.9% reported in a study among different populations including apparently healthy individuals in Plateau state 23 , but differs from 1.7% reported among ARV naïve and experienced HIV patients in Ibadan. 24 Though, varied rates of HEV IgM have been reported in other endemic regions of the world among different populations. [25] [26] [27] Thereasons for this discrepancy may range from variation in populations studied and test kits used among others.
Furthermore wide variations in reported seroprevalence of HEV antibodies in Africa during nonepidemic periods of acute and symptomatic hepatitis have been documented. 28 Additionally, studies have indicated that commercially available ELISA kits for anti-HEV antibodies differ dramatically in their sensitivity and specificity. [29] [30] [31] In our study we used an ELISA kit that has been confirmed to have the highest diagnostic sensitivity and specificity when compared to many others by several studies. 30, 32 Specifically, Vollermanet al., (2016)in a comparative study to monitor HEV antibody seroconversion in asymptomatically infected blood donors using 9 different commercially available ELISA kits reported the best performance with the kit used in this study. 33 Particularly, considerable variation for detection period of IgM antibodies was observed. Therefore, this implies that the prevalence rates of anti-HEV IgM recorded in this study are most likely true representative for the study population as at the time of testing.
Results of this study might imply that the studied communities have good supply of clean water, as drinking of fecal contaminated water has been implicated as one of the major route of HEV transmission. 34 Further, considering that HEV is known to cause acute infection 4 , a study among asymptomatic persons may not capture acutely infected individuals who might be too sick to participate in such studies.. However, this report does not underestimate the burden of acute HEV infection, especially, in resource limited countries as recent reports have confirmed outbreaks with dire consequences in different parts of sub-Saharan Africa including the Northern part of Nigeria. 35, 36 This therefore calls for the establishment of a robust surveillance system with focus on HEV that currently seems to be neglected.
The rate of 0.4% found among the pregnant women is in agreement with the rates of 0.5%,0.6% and 0.67% reported among pregnant women in different regions of the world including Africa. [37] [38] [39] Our finding, though higher than 0% rate reported in a similar cohort in France, 40 is lower than rates ranging from 2.6%-33% recorded by several authors in a similar cohort in different regions of the world. [41] [42] [43] [44] [45] Variation in the performance of different ELISA kits employed in these studies may account for the difference in rates reported.
The fact that the only pregnant woman with HEV IgM in this study was in her 33 rd week of gestation, signifies a recent exposure to HEV and the medical significance of the case. The reason being that acute HEV in pregnancy can progress to fulminant hepatitis with a high mortality rate, especially, if it occurs in the 3 rd trimester. 17 Further, reports have shown that HEV infection during pregnancy can lead to maternal mortality rate of 15% to 25%, especially, with genotype 1 which together with genotype 2 are prevalent in the developing countries. 46 Acute HEV infection during pregnancy is associated with dire consequences for the unborn, including high rate of miscarriage, stillbirth, neonatal death, high risk of vertical transmission and high risk of preterm delivery with poor neonatal survival rates. 47, 48 It was reported that HEV infection might be responsible for 2,400 to 3,000 stillbirths each year in developing countries, with many additional fetal deaths linked to antenatal maternal deaths. 49 It is worth mentioning that we do not have information on the outcome of this singular woman's pregnancy. Hence, we could not document the impact of the HEV infection in the 3 rd trimester of pregnancy on either the mother or child.
Recent outbreaks of HEV infection have been documented among Nigerian refugees in Chad and
in the Northern part of Nigeria with a significant number of pregnant women being affected . 35, 36, 50 With all the health challenges posed by acute HEV infection (especially among pregnant women) it is still grossly under reported in developing countries including Nigeria. For example, there are no laid down policies on HEV management in the country. The pregnant woman with detectable HEV IgM has documented report of fever and jaundice within the preceding 2 weeks prior sampling. Thus, it is probable that the symptoms were as a result of HEV infection, since the woman tested negative to other viral infections with the possibility of showing similar symptoms 51 . Laboratory screening for acute HEV infection is rarely done in Nigeria and more scarcely among pregnant women even when presenting with symptoms suggestive of hepatitis infection (especially when there is no outbreak). Routinely, HBV is the only hepatitis virus pregnant women are screened for in Nigeria. Therefore, it is safe to assume that screening for HEV IgM was not carried out for this woman at the ante-natal clinic. Thus, she obviously might not have been managed for HEV infection. This brings to light how acute HEV infections are possibly missed despite its clinical and epidemiological implications for the subject and the population, respectively.
Conclusion
We documented acute HEV infection in a pregnant woman in Ibadan, Oyo State, Southwest Nigeria, and reported zero prevalence rates of acute HEV infection among asymptomatic community dwellers in two different locations in the country. Consequently, we recommend more extensive studies on HEV infection in the population in a bid to define the dynamics of this neglected viral infection. In addition, we recommend the introduction of HEV IgM screening for pregnant women in Nigeria. The public should be educated on HEV, its modes of transmission and intervention strategies including vaccination in accordance with the WHO recommendations for safe vaccine. 52
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